Mg

48 articles

About Mg coverage

The Mg news hub on Global Investing News tracks 48 recent headlines that matter to investors, policy watchers, and market strategists. Use this page to monitor how Mg developments affect earnings expectations, sector rotation, supply chains, regulation, and cross-asset volatility. Stories are grouped by source type — market data, company announcements, regulatory filings, and expert analysis — so you can scan the signal quickly without wading through duplicate wire copy. When a headline links to a full article, you will find expanded context, key facts, and prediction-market angles where available. Bookmark this hub if you follow Mg across quarters; new items are added as our crawl pipeline ingests fresh sources throughout the trading day.

Explore related topics

AI Streaming Video Tech Crypto EV Economy Cloud Semiconductors Entertainment Mobile Markets Business

Latest Mg headlines

Market Data

(5)

$AAPL

S&P 500, Dow End Lower As Investors Shrug Off Cooler-Than-Expected Inflation Data — MGM, SPCX, AAPL, TSM In Focus

Yahoo Finance•about 1 month ago

US Stock Futures Flat After S&P500, Dow End At Record Highs On Strong Earnings, Easing Geopolitical Concerns — PLTR, AZN, CMG, MRNA In Focus

Yahoo Finance•3 months ago

MGK Holds 46 Percent in Just Five Stocks, And That Concentration Is Driving Most of Its Recent Gains

Yahoo Finance•6 months ago

IWO spreads its bets; MGK concentrates them

Yahoo Finance•6 months ago

Here’s Why Scotts Miracle-Gro Company (SMG) Attracts Fresh Investor Interest This Quarter

Yahoo Finance•6 months ago

Expert Analysis

(1)

$AMGN

Amgen Q3 Preview: Obesity Pipeline and Rare Disease Portfolio in Focus Ahead of November 3 Print

Amgen (AMGN) is scheduled to report its third-quarter 2026 financial results on November 3, after the market close. The biotechnology giant faces a critical test as investors look for sustained momentum following its integration of Horizon Therapeutics and progress in its high-stakes metabolic pipeline. Wall Street consensus currently estimates Earnings Per Share (EPS) of $5.91 on revenue of $10.27 billion. The quarter’s performance will likely hinge on the commercial trajectory of Tepezza and Krystexxa, alongside the volume growth of its core oncology and inflammation franchises. Key metrics for this release include updates on MariTide, Amgen’s injectable GLP-1/GIP receptor antagonist. With the obesity market reaching a fever pitch, any granular data regarding Phase 3 progress or manufacturing capacity could trigger significant volatility. Historically, Amgen has demonstrated a robust ability to manage operating margins, though increased R&D spending for its late-stage pipeline remains a point of scrutiny. The company has a consistent track record of meeting or slightly exceeding EPS estimates, having beaten consensus in three of the last four quarters. Potential market impact will be driven by the 2026 full-year guidance narrow. If Amgen signals that its biosimilar defense strategy is holding firm against legislative pricing pressures and competition, the stock could see a valuation re-rating. Conversely, any softness in the rare disease segment or delays in clinical timelines could weigh on the share price. Analysts will also be listening for updates on the capital allocation strategy, specifically regarding debt reduction following recent large-scale acquisitions.

GIN Earnings Preview•9 days ago

Get alerts for this topic

Subscribe to receive updates about "Mg"